Singh, S., Gleason, C., Fang, M., Laimon, Y., Khivansara, V., Xie, S., . . . Oser, M. (2024). Cyclin A/B RxL macrocyclic inhibitors to treat cancers with high E2F activity.
Chicago-referens (17:e uppl.)Singh, S., et al. Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity. 2024.
MLA-referens (9:e uppl.)Singh, S., et al. Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity. 2024.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.